Dr. Haake is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2220 Pierce Ave
777 PRB
Nashville, TN 37232Phone+1 615-343-3740
Education & Training
University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2011 - 2015
University of North Carolina HospitalsResidency, Internal Medicine, 2009 - 2011
University of Miami Leonard M. Miller School of MedicineClass of 2009
Certifications & Licensure
TN State Medical License 2015 - 2025
FL State Medical License 2011 - 2016
NC State Medical License 2009 - 2011- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer Start of enrollment: 2021 Jan 06
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 37 citationsStrategies to overcome therapeutic resistance in renal cell carcinoma.Peter J. Siska, Kathryn E. Beckermann, W. Kimryn Rathmell, Scott M. Haake
Urologic Oncology. 2017-03-01 - 867 citationsComprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.W. Marston Linehan, Paul T. Spellman, Christopher J. Ricketts, Chad J. Creighton, Suzanne S. Fei
The New England Journal of Medicine. 2016-01-14 - 76 citationsHypoxia-induced epithelial to mesenchymal transition in cancer.Robert Y. Hapke, Scott M. Haake
Cancer Letters. 2020-09-01
Press Mentions
Grant to Support Haake’s Research on Kidney CancerFebruary 17th, 2022
Kidney Cancer Patient, Survivor Event Set for Sept. 9August 17th, 2017- Kidney Cancer Educational Conference at VICC Set Sept. 10September 2nd, 2016
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
